Insight Molecular Diagnostics Inc

Insight Molecular Diagnostics Inc operates as a precision diagnostics company in the United States and internationally The company develops and commercializes laboratory developed tests kitted research use only tests and kitted clinical tests It is developing DetermaCNI a bloodbased monitoring tool that detects progression early after one cycle cancer treatment and DetermaIO a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies The company also offers VitaGraft Kidney a bloodbased transplant monitoring test that quantifies the concentration of donorderived cellfree DNA for kidney transplantation VitaGraft Liver a bloodbased transplant monitoring test that quantifies the concentration of donorderived cellfree DNA for liver transplantation and GraftAssure a ddcfDNA test that uses droplet digital PCR technology to measure the concentration of ddcfDNA using 48 predefined SNPs In addition it provides testing services for biomarker discovery assay design and development clinical trial support and various biomarker tests The company has a collaboration agreement with BioRad Laboratories Inc for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using BioRads ddPCR instruments and reagents Insight Molecular Diagnostics Inc was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc in June 2025 Insight Molecular Diagnostics Inc was incorporated in 2009 and is based in Nashville Tennessee